Drug Metabolism LIMS in Demand for Clinical Studies
News Jun 24, 2009
LabLogic Systems reports a rapid rise in the number of clinical studies being performed using its drug metabolism LIMS Debra.
The increase is apparently a response to the MIST* guidance document 'Safety Testing of Drug Metabolites' released by the FDA in February 2008, which clarifies the Administration’s position on when metabolites should be identified and characterized.
The document, which applies to small molecule drug candidates only, states that the FDA "strongly recommend in vivo metabolic evaluation in humans be performed as early as possible.” Metabolites that raise a safety concern are those produced in humans at greater than 10% of parent drug systemic exposure at steady state.
Huw Loaring, LabLogic’s systems director, said “Some of our pharmaceutical and contract research customers have always used Debra to collect data from human mass balance studies, but we have seen a marked increase in enquiries relating to this work recently.
“Debra facilitates the collation of patient data and calculates cumulative recovery immediately, so users find it easier to make decisions about the duration of sample collection and to report validated data.”
As well as Debra, LabLogic offers the B-RAM Model 5 RHPLC flow-through detector with SoFie stop flow for low level sample analysis - all the tools laboratories performing human radio-labelled studies need to detect and characterize metabolites derived from the parent drug.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018